# Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-302)

> **NCT03948646** · PHASE3 · COMPLETED · sponsor: **Botanix Pharmaceuticals** · enrollment: 351 (actual)

## Conditions studied

- Axillary Hyperhidrosis

## Interventions

- **DRUG:** Sofpironium Bromide, 15%
- **DRUG:** Vehicle

## Key facts

- **NCT ID:** NCT03948646
- **Lead sponsor:** Botanix Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-04
- **Primary completion:** 2021-08-13
- **Final completion:** 2021-08-13
- **Target enrollment:** 351 (ACTUAL)
- **Last updated:** 2024-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03948646

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03948646, "Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-302)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03948646. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*